Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody

Brolucizumab Biosimilar uses the same protein sequences as the therapeutic antibody brolucizumab. Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.

Product Details
Species Reactivity	Human
Source	Mammalian cells
Host/Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Immunogen	The human vascular endothelial growth factor A (VEGF-A)
Clone	Brolucizumab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	26.18 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered PBS solution, pH 7.4